Ranbaxy
Ranbaxy (India) holds 0 active US FDA Type II Drug Master Files and 1 inactive and has DMF or CEP filings on record for 1 active ingredient. 14 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Ranbaxy: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/ranbaxy
Overview
Ranbaxy is a pharmaceutical company headquartered in Gurgaon, India.
Active ingredients with DMF or CEP filings
Substances for which Ranbaxy holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
Ranbaxy holds 0 active (1 total) FDA Type II Drug Master File. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- ACYCLOVIR DRUG SUBSTANCEInactive1996-10-08
FDA compliance signals
14 FDA enforcement records linked to this company.
- recall — Class II2015-08-12
Incorrect/Undeclared Excipients: Product contains undeclared FD&C Yellow No. 5 in the capsule shell.
- recall — Class II2014-03-05
Presence of Foreign Tablets: A product complaint was received by a pharmacist who discovered an Atorvastatin 20 mg tablet inside a sealed bottle of 90-count Atorvastatin 10 mg.
- recall — Class III2013-02-20
Crystallization: Recall is due to a non-characteristic gritty/sandy texture to the product which is likely due to some crystallization of the product.
- recall — Class III2013-02-20
Crystallization: Recall is due to a non-characteristic gritty/sandy texture to the product which is likely due to some crystallization of the product.
- recall — Class II2012-12-05
Presence of Particulate Matter: Certain batches of Atorvastatin tablets 10 mg, 20 mg and 40 mg may contain small glass particulates.
- recall — Class II2012-12-05
Presence of Particulate Matter: Certain batches of Atorvastatin tablets 10 mg, 20 mg and 40 mg may contain small glass particulates.
- recall — Class II2012-12-05
Presence of Particulate Matter: Certain batches of Atorvastatin tablets 10 mg, 20 mg and 40 mg may contain small glass particulates.
- recall — Class II2012-11-28
Adulterated Presence of Foreign Tablets: A product complaint was received by a pharmacist who discovered an Atorvastatin 20 mg tablet inside a sealed bottle of 90-count Atorvastatin 10 mg.
- recall — Class III2012-07-11
Subpotent (Single Ingredient Drug): out-of-specification result for coal tar content assay.
- 4832011-06-22
Late submission of 15-day report
- 4832011-06-22
Incomplete periodic safety report
- 4832011-06-22
Submission of report follow-up
- 4832011-06-22
Failure to develop written procedures
- 4832009-09-29
Investigations of discrepancies, failures
Is this Ranbaxy?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Related companies
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.